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SUMMARY
Survival from colorectal cancer has not improved over the last four decades
despite advances in surgery and anaesthesia. The answer to the question
whetheradjuvant chemotherapy and radiotherapy will improve survivalfrom
the disease can only come from randomised, controlled trials. In the future,
immunotherapy and gene therapy may be ofbenefit but these are still many
years from the clinical arena. We believe that current evidence suggests that
patients with Dukes' B and Ccolorectal cancershould be entered into trials of
adjuvant therapy. This evidence is reviewed below along with estimates ofthe
impact that adjuvant therapy would have on the outcome from this disease in
Northern Ireland.
There are approximately 600 new cases of newly-diagnosed pathologically
proven colorectal carcinoma in Northern Ireland annually.' This disease
accounts for an average of 440 deaths yearly in our community.2 Colorectal
cancer is the second most common cause of death from malignancy in adults
in this population. The Northern Ireland colorectal cancer register has found
that the proportion of tumours using Dukes' staging was as follows: Dukes' A
4%, Dukes' B 50%, Dukes' C 28%, Dukes' D 18%.
These figures were calculated using the Astler-Coller Modification of Dukes'
staging:3 A - mucosal (ie intramucosal and submucosal), B - into or through
the colonic muscle wall, C - one or more lymph nodes involved, and D - distant
metastases present. Survival figures for colorectal cancer have not improved
over the last few decades despite advances in medical care. Using the above
version of Dukes' staging, five-year survival figures 4 are: A - virtually 100%;
B - range 30%-85%, average 70%; C - range 30%-60%, average 45%; and D -
under 5%.
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Potentially curative surgery is possible in around 75%ofnew cases ofcolorectal
cancer, but long-term follow-up reveals that around half of these "cured"
patients will develop incurable recurrence of colorectal cancer.5 There is no
indication for adjuvant treatment in Dukes' A colorectal cancer. The hazards of
currently available therapies outweigh the benefits in a disease with 98-100%
five-year survival. Equally, patients with Dukes' D or incurable disease cannot
receive adjuvanttherapy butmaybenefitfrom additionaltherapy afterpalliative
surgery. This may result in improvements in both survival time and quality of
life.6
There are approximately 600 cases in Northern Ireland annually. From the
stage distribution above we expect there to be about 470 cases in the Dukes'
B and C groups. Estimates of five year survival applied to the projected 470
cases per annum in Duke's B and C would give a five year mortality overall of
40%.
We believe that patients with Dukes' B and C colorectal cancer should be
enrolled in a randomised, controlled trial ofadjuvant therapy. This would entail
treatment arms of modulated 5-fluorouracil chemotherapy for colon cancer
and radiotherapy and chemotherapy for rectal cancer. Statistical calculations
show that a trial of520 patients (260 per treatment group) will have 80% power
to detect a statistically significant 30% relative reduction in mortality with
adjuvant therapy (P<0.05; two-tailed). This would represent a mortality in the
treatment groups of 28% compared to 40% and is approximately equivalent to
the long term survival ofone in every eight patients who currently die within five
years.
Although some Dukes' B and C stage patients are currently offered adjuvant
therapy in Northern Ireland, this remains a very small proportion (<10%) ofthe
total. Northern Ireland is an ideal area fora trial ofadjuvanttherapy in colorectal
cancer as we have one of the highest incidences of this cancer in the world ',
and our population has low rates of immigration, emigration and mobility
compared to the rest of the United Kingdom, allowing excellent follow-up;
clinical trials are possible without dissipation of patients between health
authorities, hospitals and regions because of our small size, and easy
communication between consultants. At present adjuvant therapy is not often
offered to suitable patients.
It is anticipated that the necessary sample size of a minimum of 520 patients
could be accrued in Northern Ireland within three years. A larger multicentre
trial would greatly increase the number of patients and a national study is
currently being proposed by the United Kingdom Co-ordinating Committee on
Cancer Research which will have multiple arms of varying chemotherapy
regimens. However, recent experience has shown that local recruitment from
Northern Ireland into national studies in colorectal cancer such asthe AXIStrial
of intraportal chemotherapy and the Medical Research Council trial of
chemotherapy in advanced colorectal cancer is very low.
Chemotherapy
Previous trials have shown that 5-fluorouracil, either singly or in combination
with other agents is the most effective adjuvant systemic chemotherapeutic
Aqent.' This substance is a prodrug which is metabolised in place of uracil or
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orotate in the de-novo or salvage pathways ofgeneration ofuridine nucleotides
producing a cytotoxic insult through effects on translation, transcription,
mitosis or DNA synthesis.8 Folinic acid in combination with 5-fluorouracil is
more effective than 5-fluorouracil alone due to inhibition of thymidylate
synthetase.9 A combination of 5-fluorouracil and folinic acid would be
administered according to the 48-hour infusion regime used by the ICRF
medical oncology department at St Bartholomew's Hospital.10 Chemotherapy
should commence at two weeks postoperatively unless there are wound or
other postoperative complications and must occurwithin six weeks ofsurgery.
Folinic acid is administered at 200mg/M2 (maximum dose 350mg) by
intravenous infusion in 250ml normal saline overtwo hours. This is followed by
an intravenous bolus of400mg/M2 5-fluorouracil in 100ml normal saline over
15 minutes followed by an intravenous infusion of400 mg/M2 5-fluorouracil in
1000ml normal saline over 18 hours. The above regimen is given on two
consecutive days as an in-patient and repeated every two weeks for a total of
eight courses (sixteen days of in-patient stay over four months).
The original report of this regimen showed a low incidence of toxicity. In 64
patients with advanced adenocarcinoma, none had toxic effects greater than
WHO Grade 11, 9% developed mucositis, 12% diarrhoea and 3% significant
neutropaenia. No dose-reduction was necessary and 97% of treatments were
given as planned. It is expectedthatthese figures will be even betterwhen given
in an adjuvant setting, as has already been the experience in the Northern
Ireland Centre For Clinical Oncology. When this regimen was used in Belvoir
Park Hospital as adjuvant treatment for colorectal cancer, gastrointestinal
upset occurred in under 10% of cases and significant neutropenia has not
occurred. The 48 hour infusion schedule results in much lower toxicity and
emergency hospital admissions than schedules using daily bolus injections.
Data from Austria from a randomised trial on the use of modulated 5-
fluorouracil in advanced disease suggests that chemotherapy often results in
mild to moderate gastrointestinal symptoms6 but does not result in a decrease
in quality of life scores. Indeed, in patients with poor quality of life from
symptoms of their disease before treatment, there was an improvement with
chemotherapy.
Radiotherapy
The area most at risk of local recurrence of rectal cancer below the peritoneal
reflection is the posterior pelvis. Radiation enteritis is avoided by using fields
limiting high radiation doses to this volume. Prone positioning to prevent
irradiation of loops of small bowel will also decrease complications. The
treatment fields should centre on the siteofthe resected tumour and includethe
lateral pelvic nodes. The postoperative radiotherapy should commence as
soon as possible but must be within six weeks of resection. The dosage ranges
suggested are 40-50 Gy delivered in 20-25 daily fractions over a four to five
week period and may precede or run concurrently with chemotherapy.
Summary ofPrevious trials
One halfofpatients with colorectal cancer diewith distantdisease.5 The disease
is systemic and occult micrometastases are commonly present in patients who
have undergone apparently complete tumour resection. Dissemination often
occurs before the primary tumour becomes clinically apparent and this
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characteristic has prevented improvements in cure rates despite advances in
surgical and anaesthetic techniques. In order to improve the prognosis by
eliminating micrometastases, a numberofinvestigations havestudiedadjuvant
chemotherapy but its value in colorectal cancer remains unclear. Many trials
have taken place, with great variation in the use of randomisation, patient
numbers, particular chemotherapeutic regimens and the duration offollow-up.
Chemotherapy trials
Chemotherapy trials in colorectal cancer using 5-fluorouracil alone have
demonstrated it to be the best single agent. However, large studies by the
Veterans Administration Surgical Adjuvant Group1' and Central Oncology
Group'2 demonstrated only minor activity. Overall, single agent chemotherapy
with 5-fluorouracil has given a reduction in mortality of 10% at best. The
Veterans Administration Surgical Adjuvant Group later administered low-dose
intravenous 5-fluorouracil plus oral lomustine.13They demonstrated prolonged
disease-free survival in Dukes' C patients but no improvement in overall
survival. The Gastrointestinal Tumour Study Group'4 studied the use of 5-
fluorouracil plus lomustine with or without BCG immunotherapy against BCG
alone, and against controls. They found no improvement in survival and the
furtherproblemthatlomustinewasassociatedwith increased riskofleukaemias.
The SouthWestOncologyGroup'5 compared 5-fluorouracil and lomustine with
or without BCG against controls and found no survival benefit at seven years.
The National Surgical Adjuvant Breast and Bowel Project (NSABP)16 compared
adjuvant 5-fluorouracil, lomustine and vincristine against BCG and controls,
and demonstrated an 8% improvement in survival after five years.
Windle et al17 compared adjuvant 5-fluorouracil with levamisole against
levamisole alone and controls. After eight years, they found improved survival
in Dukes' C patients with combination chemotherapy. Levamisole is an anti-
helminthic drug with immunostimulatory properties and has been used as
adjuvant cancer treatment in the last two decades either alone, or with
radiotherapy or chemotherapy,'8 but with unclear results on survival. The
European Organisation for Research and Treatment of Cancer group
demonstrated recently thatby itselfithas no adjuvant effect in colonic cancer,'9
although it is standard practice in the LISA to combine levamisole with 5-
fluorouracil in treatment of colorectal cancer. The mechanism of action of
levamisole is unclear and 5-fluorouracil alone may be responsible for the
observed effects on survival in trials on the combination of 5-fluorouracil and
levamisole. 20
TheNorthCentral CancerTreatmentGroup (NCCTG)21 compared 5-fluorouracil
plus levamisole against levamisole and controls. They also showed increased
survival with combination chemotherapy in Dukes' C patients. A larger
intergroupstudywas performed toconfirmthese results andenrolledthreetime
more patients.22 They showed that this combination chemotherapy increased
survival in Dukes' C patients by 33% and decreased recurrence by 41%.
Levamisole alone was no betterthan the untreated controls. There was no clear
benefit in patients with Dukes' B disease. The addition of folinic acid to 5-
fluorouracil resulted in improvements in response, quality of life and survival
in the NCCTG study in advanced colorectal cancer.23 There is also considerable
discussion on the best route for administering adjuvant chemotherapy -
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intrahepatic, intraperitoneal, intraportal or intravenous. Ofthese, the latter two
are of most current interest. Hepatic metastases are the commonest cause of
failure following surgery for colorectal cancer and these presumably arise from
haematogenous spread via the portal vein. Portal infusions are an attempt to
target the chemotherapy to the liver and to limit toxicity. These are usually
given in conjunction with heparin for a short period of about a week. The
treatment is well tolerated without significant hepatic toxicity24 but results have
been very conflicting. Tayloretal 25 showedsignificant improvement in survival
following portal vein infusions of5-fluorouracil particularly in Dukes' B lesions.
The NSABP conducted a similar, but much larger trial of seven day portal vein
infusion of5-fluorouracil versus no postoperative adjuvanttreatment in Dukes'
A, B and C disease.26 They observed an 8% improvement in survival with intra-
portal 5-fluorouracil butno reduction inclinicallydetectablehepaticmetastases.
The Large Bowel Cancer Project failed to reveal any improvement in survival
or incidence of liver metastases with intra-portal 5-fluorouracil and heparin
infusio.24 There is no evidence currently that portal-vein infusion is superior to
systemic intravenous administration. The NSABP recently reported a trial
designed to evaluate the efficacy of folinic acid-modulated 5-fluorouracil in
adjuvanttherapy ofDukes' B and C colon cancer.27 They found thatfolinic acid
and 5-fluorouracil treatment significantly prolongs disease-free survival with a
32% reduction in mortality risk compared to a control group randomised to
receivelomustine, vincristineand5-fluorouracil. Furtherevidencethatmodulated
5-fluorouracil may be beneficial came in a meta-analysis of nine randomised
prospective clinical trials with 1381 patients with advanced colorectal cancer;
this demonstrated a 23% objective response rate with folinic acid and 5-
fluorouracil.28
Radiotherapy Trials
The object of adjuvant radiotherapy is to prevent the further growth of cancer
cells not removed at the time of surgery. Radiotherapy results in cytotoxicity
principally by damaging DNA, thereby interfering with the ability of cells to
reproduce. It was initially thought that adjuvant radiotherapy after surgery for
rectal cancer would reduce the risk of local recurrence and thereby improve
survival rates. The incidenceofpelvic recurrence isvariable, withfiguresof 10%
to 40% commonly quoted.29 The risk of recurrence increases with worsening
Dukes' stage.30 The first site of recurrence found at re-operation is often the
general area of the primary cancer31 and studies have also shown that
prevention of recurrence in the area of the primary tumour is associated with
a decreased incidence of distant metastase.32 Pelvic recurrence may be
associated with both microscopic extension of tumour to the lateral resection
margins33 and metastases in unresected pelvic wall lymph nodes.34 The
following studies examined the outcome after curative surgery with or without
postoperative radiotherapy in Dukes' B or C colorectal cancer. The
Gastrointestinal Tumor Study Group35 showed a 9% increase in five year
survival and 4% reduction in both local and extrapelvic recurrence with
adjuvant radiotherapy. The National Surgical Adjuvant Breast and Bowel
Project36 showed a 3% decrease in five year survival, 9% improvement in local
recurrence and 5% worsening in extrapelvic recurrence with radiation. The
Denmark study37 showed that radiotherapy caused no change in five year
survival, a 2% decrease in local recurrence and a 2% increase in extrapelvic
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recurrence. The Netherlands study38 showed a 10% decrease in five year
survival, 9%improvement in local recurrence and 12%worsening inextrapelvic
recurrence. Overall, these studies have shown that radiotherapy as the sole
adjuvant therapy, given either pre- or post-operatively, will reduce pelvic
recurrence but not markedly influence either survival rates or extrapelvic
recurrence.29 Reduction in pelvic recurrence is worthwhile as this is often
difficult or impossible to control, and symptoms are often severe and result in
a very poor quality of life.
Combined radiotherapy and chemotherapy trials
The failure of adjuvant chemotherapy to lower pelvic recurrence and of
adjuvant radiotherapy to lower extrapelvic recurrence or mortality rates has
resulted in establishment of trials of adjuvant combination therapy. The
following studies examined the outcome after curative surgery and post-
operative radiotherapy with or without chemotherapy in Dukes' B and C
colorectal cancer. The Gastrointestinal Tumor Study Group35 39 trial had five
year survivals of 43% with surgery alone, 52% with adjuvant radiotherapy and
59% with combination radiotherapy and chemotherapy. The local recurrence
rates were 24%, 20% and 1 1% respectively and extrapelvic recurrence rates
34%, 30%and 26%. The NCCTG trial40hadfiveyearsurvival of47%foradjuvant
radiotherapy and 58% for adjuvant combination therapy. The local recurrence
rateswere 25%and 14% respectively, andextrapelvic recurrence rates46% and
29%. Anotherstudy,41 however, showed no significant improvement in survival
with combination chemotherapy and radiotherapy over one or other of the
adjuvantmodalitiesalone.Thecombinationsofradiotherapy andchemotherapy
used in the trials described were fairly well tolerated. The risks of serious late
morbidity such asenteritis andtreatment-related mortalitywerebroadlysimilar
to those of patients treated with radiotherapy alone.
Conclusion
Previous trials of adjuvant therapy in colorectal cancer have suggested a
modestsurvivalbenefit. Recentevidenceshowsthatmodulationof5-fluorouracil
with folinic acid results in greater efficacy with acceptable toxicity. We believe
that a local, randomised, controlled trial can accrue sufficient patients to allow
ustodemonstratewhetheradjuvanttherapyofcolorectal cancerusingmodulated
5-fluorouracil provides worthwhile improvement in survival in this common
disease.
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